Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 35th Annual Meeting of the Infectious Diseases Society of America
Impact of DMP-266, A New, Unapproved NNRTI, with Indinavir, and D4T

September 1997

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Dr. S. Riddler of the University of Pittsburgh reported for the DMP-266 clinical development team on the 48 week data for a cohort of asymptomatic patients treated with DMP-266 (200 mg/d), a nonnucleoside reverse transcriptase inhibitor, with Indinavir (800 or 1000mg/tid). The patients had a mean baseline plasma HIV RNA of 5.06 log10 copies of HIV RNA/ml and mean CD4 count of 283 cells/mm3. 71% had prior nucleoside therapy. In the course of the study, 42 of the 59 patients who initially enrolled added D4T to their regimen at 12 weeks, and all points had their DMP-266 dose increased to 600 mg/d after 36 weeks of treatment. By 44 weeks, 89% of the patients who received DMP266 plus Indinavir had PVL less than 400 copies/ml, and 77% of the patients who also were on D4T had PVL that were below the limits of detection. The regimens were generally well-tolerated, with only 2 persons in either treatment arm withdrawing because of side effects, which included infrequent rashes, but none that were severe or persistant. DMP-266 appears to be a very well tolerated new NNRTI compound which can be given once daily and adds to the potency of Indinavir therapy.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More on HIV Medications
Efavirenz (Sustiva, Stocrin)



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement